H.A. Burris

Activity of Topotecan, a New Topoisomerase I Inhibitor, Against Human Tumor Colony-Forming Units In Vitro

H.A. Burris, Axel‐R. Hanauske, Randall K. Johnson et al. · JNCI Journal of the National Cancer Institute · 1992 · 170 citations

Medicine, Oncology, Pharmacology +13

LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)

G. N. Hortobágyi, Salomon M. Stemmer, H.A. Burris et al. · Annals of Oncology · 2021 · 74 citations

Medicine, Oncology, Pharmacology +17

Clinical trials with the topoisomerase I inhibitors.

H.A. Burris, M.L. Rothenberg, John G. Kuhn et al. · PubMed · 1992 · 62 citations

Medicine, Oncology, Pharmacology +8

A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors

Josep Tabernero, Federico Rojo, H.A. Burris et al. · Journal of Clinical Oncology · 2005 · 62 citations

Medicine, Oncology, Pharmacology +17

A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC)

M. Beeram, Ian E. Krop, Shanu Modi et al. · Journal of Clinical Oncology · 2007 · 40 citations

Medicine, Oncology, Pharmacology +17